



*Certificate delivered by the European Commission,
as the institution managing Horizon 2020,
the EU Framework Programme for Research and Innovation 2014-2020*

The project proposal **767871, LENTISOMA**

Safeguarding gene therapy: LENTISOMA an innovative safeEfficient vehicle for medicinal genes

Submitted under the Horizon 2020's **SME instrument phase 2**
call **H2020-SMEInst-2016-2017 (H2020-SMEINST-2-2016-2017)** of **18 January 2017**
in the area of

Supporting innovative SMEs in the healthcare biotechnology sector

by

VIVEBIOTECH S.L.

Paseo Mikeletegi 81
20009 San Sebastian
Spain

following evaluation by an international panel of independent experts

**WAS SUCCESSFUL IN A HIGHLY COMPETITIVE EVALUATION PROCESS*
AS A HIGH QUALITY PROJECT PROPOSAL**

This proposal is recommended for funding by other sources since Horizon 2020 resources available for this specific Call were already allocated following a competitive ranking.

* This means passing all stringent Horizon 2020 assessment thresholds for the 3 award criteria (excellence, impact, quality and efficiency of implementation) required to receive funding from the EU budget Horizon 2020.

Corina Cretu,
Commissioner for
Regional Policy

Carlos Moedas,
Commissioner for Research,
Science and Innovation

Brussels, 07/03/2017